8-K
filed December 19, 2022, 6:59 PM ET
ticker TLSI
CIK 0001826667
other material
confidence high
sentiment negative
materiality 0.65
TriSalus Life Sciences, Inc. (TLSI): debt financing — MedTech shareholders approve deadline extension; 96% of public shares redeemed, leaving ~$19.7M in trust
TriSalus Life Sciences, Inc.
- Stockholders approved extension of business combination deadline from Dec 22, 2022 to June 22, 2023.
- 23,046,578 Public Shares (96%) redeemed for ~$232.37M; only ~$19.70M remains in trust after redemptions.
- Sponsor issued up to $468,821 Extension Note and up to $1,000,000 Working Capital Note for extension and working capital.
- Directors Karim Karti, Martin Roche, Thierry Thaure, Manuel Aguero re-elected as Class I directors.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TriSalus Life Sciences, Inc. incurred loan of up to $468,821.28 with MedTech Acquisition Sponsor LLC maturing upon the date of the consummation of an initial business combination.
- Instrument
- loan
- Principal
- up to $468,821.28
- Counterparty
- MedTech Acquisition Sponsor LLC
- Maturity
- upon the date of the consummation of an initial business combination
- Event
- incurrence
Exact text from the filing
On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28 (the “Extension Funds”) to deposit into the Company’s trust account (the “Trust Account”) for the shares of Class A common stock of the Company (the “Public Shares”) that were not redeemed in connection with the extension of the Company’s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the board of directors of the Company (the “Board”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TriSalus Life Sciences, Inc. incurred loan of up to $1,000,000 with MedTech Acquisition Sponsor LLC maturing the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its a.
- Instrument
- loan
- Principal
- up to $1,000,000
- Counterparty
- MedTech Acquisition Sponsor LLC
- Maturity
- the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its a
- Event
- incurrence
Exact text from the filing
on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes, , which may be drawn down from time to time upon request by the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
TriSalus Life Sciences, Inc.: Amended certificate of incorporation to extend business combination deadline from December 22, 2022 to June 22, 2023 (effective 2022-12-12).
- Change
- charter amendment
- Effective
- 2022-12-12
Exact text from the filing
On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Extension Amendment”) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TriSalus Life Sciences, Inc. entered into Working Capital Note with MedTech Acquisition Sponsor LLC valued at up to $1,000,000 (effective 2022-12-16).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- MedTech Acquisition Sponsor LLC
- Value
- up to $1,000,000
- Effective
- 2022-12-16
Exact text from the filing
on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TriSalus Life Sciences, Inc. entered into Extension Note with MedTech Acquisition Sponsor LLC valued at $468,821.28 (effective 2022-12-16).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- MedTech Acquisition Sponsor LLC
- Value
- $468,821.28
- Effective
- 2022-12-16
Exact text from the filing
On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal - to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). at the 2022-12-22 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2022-12-22
Exact text from the filing
(1) The Extension Amendment Proposal — a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 20,943,728 2,962,183 32,602
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TriSalus Life Sciences, Inc. shareholders approved Director Election Proposal - to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified..
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
(2) The Director Election Proposal — to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified. The following is a tabulation of the votes with respect to the election of directors, each of whom was elected by the Company’s stockholders: Name FOR ABSTAIN Karim Karti 19,508,998 4,429,515 Martin Roche, MD 20,704,879 3,233,634 Thierry Thaure 20,704,623 3,233,890 Manuel Aguero 20,704,875 3,233,638
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.